Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

Sepsis

Therapeutic area intelligence for Sepsis with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

Recent signals(3)

ClinicalJuly 29, 2026

Study on ICU-Acquired Weakness and Cardiovascular Impairment in Sepsis Patients

The University of Manitoba is investigating the impact of sepsis on cardiovascular function and microcirculation in ICU patients.

ClinicalJuly 11, 2026

FMT Shows Promise in Restoring Gut Microbiome in Antibiotic-Treated Sepsis Patients

Fecal microbiota transplantation (FMT) significantly improved gut microbiome diversity in antibiotic-treated sepsis patients compared to probiotics.

July 8, 2026

Study on Sepsis-Associated Acute Lung Injury from Hypervirulent Klebsiella Pneumoniae Launched

A prospective observational study will assess the risk of sepsis-associated acute lung injury from hypervirulent Klebsiella pneumoniae compared to classical strains.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.